Adia Nutrition（ADIA）株式概要アディア・ニュートリション社は、プロバイオティクス・チュースとドリンクミックスを製造している。 詳細ADIA ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6報酬過去 1 年間で収益は353.4%増加しましたリスク分析マイナスの株主資本 US市場と比較して、過去 3 か月間の株価の変動が非常に大きいキャッシュランウェイが1年未満である 収益が 100 万ドル未満 ( $805K )+2 さらなるリスクすべてのリスクチェックを見るADIA Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.161.4k% 割高 内在価値ディスカウントEst. Revenue$PastFuture-442k805k2016201920222025202620282031Revenue US$805.0kEarnings US$78.1kAdvancedSet Fair ValueView all narrativesAdia Nutrition, Inc. 競合他社Natural Alternatives InternationalSymbol: NasdaqGM:NAIIMarket cap: US$15.5mBonkSymbol: NasdaqCM:BNKKMarket cap: US$15.6mChina Foods HoldingsSymbol: OTCPK:CFOOMarket cap: US$13.4mHealthy ExtractsSymbol: OTCPK:HYEXMarket cap: US$19.1m価格と性能株価の高値、安値、推移の概要Adia Nutrition過去の株価現在の株価US$0.1652週高値US$0.2852週安値US$0.023ベータ-8.571ヶ月の変化-17.91%3ヶ月変化-15.79%1年変化113.33%3年間の変化471.43%5年間の変化704.02%IPOからの変化0%最新ニュースお知らせ • Jan 08Adia Nutrition, Inc. Appoints Dawn Bell as Chief Revenue OfficerAdia Nutrition, Inc. announced the appointment of Dawn Bell as Chief Revenue Officer (CRO) through its subsidiary, ADIA Labs. Ms. Bell brings more than 15 years of proven expertise as a sales strategist in the medical device and pharmaceutical industries, with a strong history of driving growth and building successful partnerships. While Ms. Bell's role includes strengthening revenue for ADIA Nutrition and its laboratory operations, her primary contribution will be ensuring shared success across the entire ecosystem. She will be partnering with doctors and clinics to significantly increase their revenue by providing hands-on guidance and proven strategies to seamlessly integrate the Company's advanced regenerative therapies and diagnostic services into their practices-whether in regenerative medicine, orthopedics, pain management, wellness, or other specialties. This appointment comes at an important time as Adia Med of Winter Park prepares to launch its first Institutional Review Board (IRB)-approved clinical study focused on autism, marking a significant advancement in the Company's clinical and scientific efforts.お知らせ • Oct 22Adia Nutrition, Inc. Appoints Evan Thomas as Independent Medical Director for Its Medical Division, Adia MedAdia Nutrition, Inc. announced the appointment of Evan Thomas, MD, PhD, as an Independent Medical Director for its medical division, Adia Med. A renowned radiation oncologist and visionary, Dr. Thomas will oversee clinic practices, including the cutting-edge Autologous Hematopoietic Stem Cell Transplantation (AHSCT) program, finalizing protocols to prepare for patient intake once in-network provider status is secured with major insurers. Based in Winter Park, FL, Dr. Thomas serves as Chief Medical Officer of the Renaissance Institute of Precision Oncology &Radiosurgery. He is celebrated for his expertise in central nervous system (CNS) and functional radiosurgery, utilizing stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) to treat complex conditions. Dr. Thomas has pioneered Joint Glow, a therapy utilizing advanced radiotherapy for joint disorders, an innovative approach rare among U.S. physicians. His global influence includes clinical trial leadership, peer-reviewed publications, and lectures in over 15 countries. As Medical Director, Dr. Thomas will guide Adia Med's clinical operations, finalize AHSCT protocols, and oversee Adia Med's other specialized therapies ensuring exceptional patient care.お知らせ • Sep 11Adia Nutrition, Inc. Appoints Richard Edwards as Its Second Medical DirectorAdia Nutrition, Inc. announced the appointment of Dr. Richard Edwards, DO, as its second Medical Director. Dr. Edwards joins Dr. Monica Sher, MD, to form a diverse and highly experienced board of medical directors. This strategic expansion underscores Adia Nutritions commitment to providing exceptional care and advancing innovative treatments in the field of autologous Hematopoietic Stem Cell Transplantation (aHSCT). Dr. Edwards, a distinguished osteopathic physician, complements Dr. Shers medical expertise with his unique perspective and approach. His extensive background in osteopathic medicine and his dedication to patient-centered care align seamlessly with Adia Nutritions mission to deliver comprehensive and individualized treatment plans. Adia Nutrition is set to move forward with its next crucial step: recruiting oncologists to administer aHSCT treatments. The board and the oncologists will collaborate to review and select the safest and most effective aHSCT protocols from around the world (over 10,000 patients treated by aHSCT worldwide). They will be responsible for crafting detailed protocols and procedures tailored specifically for Adia Nutritions clinics. This process will include determining whether treatments will be administered in a hospital setting or an outpatient clinic, ensuring that all options provide the highest standards of care. In addition to protocol development, the board of medical directors will also be actively involved in evaluating potential patients. Through a thorough assessment process, they will determine which individuals are suitable candidates for aHSCT treatments, based on their medical history and treatment needs.お知らせ • Aug 23Adia Nutrition, Inc. Announces Appointment of Dr. Monica Sher as One of the Directors of Its Medical DivisionAdia Nutrition, Inc. announced appointment of Dr. Monica Sher as one of the Directors of its Medical Division, where she will be instrumental in helping to establish the policies and procedures for the company's Autologous Hematopoietic Stem Cell Transplantation (aHSCT) program for Multiple Sclerosis (MS) patients. Following a comprehensive search and selection process, Dr. Sher was chosen for her extensive experience and expertise in the field of medicine. With a background in Internal Medicine and a passion for health and wellness, she is well-suited to assist in leading ADIA Nutrition's efforts in advancing aHSCT therapies for MS.お知らせ • Apr 20Adia Nutrition, Inc. has filed a Follow-on Equity Offering in the amount of $1.5 million.Adia Nutrition, Inc. has filed a Follow-on Equity Offering in the amount of $1.5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 75,000,000 Price\Range: $0.005 to $0.02 Discount Per Security: $0最新情報をもっと見るRecent updatesお知らせ • Jan 08Adia Nutrition, Inc. Appoints Dawn Bell as Chief Revenue OfficerAdia Nutrition, Inc. announced the appointment of Dawn Bell as Chief Revenue Officer (CRO) through its subsidiary, ADIA Labs. Ms. Bell brings more than 15 years of proven expertise as a sales strategist in the medical device and pharmaceutical industries, with a strong history of driving growth and building successful partnerships. While Ms. Bell's role includes strengthening revenue for ADIA Nutrition and its laboratory operations, her primary contribution will be ensuring shared success across the entire ecosystem. She will be partnering with doctors and clinics to significantly increase their revenue by providing hands-on guidance and proven strategies to seamlessly integrate the Company's advanced regenerative therapies and diagnostic services into their practices-whether in regenerative medicine, orthopedics, pain management, wellness, or other specialties. This appointment comes at an important time as Adia Med of Winter Park prepares to launch its first Institutional Review Board (IRB)-approved clinical study focused on autism, marking a significant advancement in the Company's clinical and scientific efforts.お知らせ • Oct 22Adia Nutrition, Inc. Appoints Evan Thomas as Independent Medical Director for Its Medical Division, Adia MedAdia Nutrition, Inc. announced the appointment of Evan Thomas, MD, PhD, as an Independent Medical Director for its medical division, Adia Med. A renowned radiation oncologist and visionary, Dr. Thomas will oversee clinic practices, including the cutting-edge Autologous Hematopoietic Stem Cell Transplantation (AHSCT) program, finalizing protocols to prepare for patient intake once in-network provider status is secured with major insurers. Based in Winter Park, FL, Dr. Thomas serves as Chief Medical Officer of the Renaissance Institute of Precision Oncology &Radiosurgery. He is celebrated for his expertise in central nervous system (CNS) and functional radiosurgery, utilizing stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) to treat complex conditions. Dr. Thomas has pioneered Joint Glow, a therapy utilizing advanced radiotherapy for joint disorders, an innovative approach rare among U.S. physicians. His global influence includes clinical trial leadership, peer-reviewed publications, and lectures in over 15 countries. As Medical Director, Dr. Thomas will guide Adia Med's clinical operations, finalize AHSCT protocols, and oversee Adia Med's other specialized therapies ensuring exceptional patient care.お知らせ • Sep 11Adia Nutrition, Inc. Appoints Richard Edwards as Its Second Medical DirectorAdia Nutrition, Inc. announced the appointment of Dr. Richard Edwards, DO, as its second Medical Director. Dr. Edwards joins Dr. Monica Sher, MD, to form a diverse and highly experienced board of medical directors. This strategic expansion underscores Adia Nutritions commitment to providing exceptional care and advancing innovative treatments in the field of autologous Hematopoietic Stem Cell Transplantation (aHSCT). Dr. Edwards, a distinguished osteopathic physician, complements Dr. Shers medical expertise with his unique perspective and approach. His extensive background in osteopathic medicine and his dedication to patient-centered care align seamlessly with Adia Nutritions mission to deliver comprehensive and individualized treatment plans. Adia Nutrition is set to move forward with its next crucial step: recruiting oncologists to administer aHSCT treatments. The board and the oncologists will collaborate to review and select the safest and most effective aHSCT protocols from around the world (over 10,000 patients treated by aHSCT worldwide). They will be responsible for crafting detailed protocols and procedures tailored specifically for Adia Nutritions clinics. This process will include determining whether treatments will be administered in a hospital setting or an outpatient clinic, ensuring that all options provide the highest standards of care. In addition to protocol development, the board of medical directors will also be actively involved in evaluating potential patients. Through a thorough assessment process, they will determine which individuals are suitable candidates for aHSCT treatments, based on their medical history and treatment needs.お知らせ • Aug 23Adia Nutrition, Inc. Announces Appointment of Dr. Monica Sher as One of the Directors of Its Medical DivisionAdia Nutrition, Inc. announced appointment of Dr. Monica Sher as one of the Directors of its Medical Division, where she will be instrumental in helping to establish the policies and procedures for the company's Autologous Hematopoietic Stem Cell Transplantation (aHSCT) program for Multiple Sclerosis (MS) patients. Following a comprehensive search and selection process, Dr. Sher was chosen for her extensive experience and expertise in the field of medicine. With a background in Internal Medicine and a passion for health and wellness, she is well-suited to assist in leading ADIA Nutrition's efforts in advancing aHSCT therapies for MS.お知らせ • Apr 20Adia Nutrition, Inc. has filed a Follow-on Equity Offering in the amount of $1.5 million.Adia Nutrition, Inc. has filed a Follow-on Equity Offering in the amount of $1.5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 75,000,000 Price\Range: $0.005 to $0.02 Discount Per Security: $0株主還元ADIAUS Personal ProductsUS 市場7D-5.9%-0.5%-0.8%1Y113.3%-19.0%27.1%株主還元を見る業界別リターン: ADIA過去 1 年間で-20 % の収益を上げたUS Personal Products業界を上回りました。リターン対市場: ADIA過去 1 年間で26.7 % の収益を上げたUS市場を上回りました。価格変動Is ADIA's price volatile compared to industry and market?ADIA volatilityADIA Average Weekly Movement51.0%Personal Products Industry Average Movement7.7%Market Average Movement7.2%10% most volatile stocks in US Market16.3%10% least volatile stocks in US Market3.2%安定した株価: ADIAの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: ADIAの 週次ボラティリティ は、過去 1 年間で44%から51%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a3Larry Powaliszwww.adianutrition.comアディア・ニュートリション社は、プロバイオティック・チューとドリンクミックスを製造している。バランスベリー、無糖グリーンティー、ラズベリーレモネードスリム、レモンライムスポーツ、オレンジマンゴープロバイオティクスドリンクミックス、ベリー＆レモネードプロバイオティクスチュー、多発性硬化症の自家造血幹細胞移植治療薬を提供。同社はオンラインおよび栄養ストアを通じて製品を提供している。アディア・ニュートリション社の前身はPivX Solutions Inc.で、2004年5月に社名をアディア・ニュートリション社に変更した。同社は1999年に設立され、ハワイ州カーティスタウンに本社を置いている。もっと見るAdia Nutrition, Inc. 基礎のまとめAdia Nutrition の収益と売上を時価総額と比較するとどうか。ADIA 基礎統計学時価総額US$16.05m収益（TTM）-US$441.77k売上高(TTM)US$805.02k18.8xP/Sレシオ-34.2xPER（株価収益率ADIA は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ADIA 損益計算書（TTM）収益US$805.02k売上原価US$568.81k売上総利益US$236.21kその他の費用US$677.98k収益-US$441.77k直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.0047グロス・マージン29.34%純利益率-54.88%有利子負債／自己資本比率-172.2%ADIA の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 01:48終値2026/05/21 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Adia Nutrition, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jan 08Adia Nutrition, Inc. Appoints Dawn Bell as Chief Revenue OfficerAdia Nutrition, Inc. announced the appointment of Dawn Bell as Chief Revenue Officer (CRO) through its subsidiary, ADIA Labs. Ms. Bell brings more than 15 years of proven expertise as a sales strategist in the medical device and pharmaceutical industries, with a strong history of driving growth and building successful partnerships. While Ms. Bell's role includes strengthening revenue for ADIA Nutrition and its laboratory operations, her primary contribution will be ensuring shared success across the entire ecosystem. She will be partnering with doctors and clinics to significantly increase their revenue by providing hands-on guidance and proven strategies to seamlessly integrate the Company's advanced regenerative therapies and diagnostic services into their practices-whether in regenerative medicine, orthopedics, pain management, wellness, or other specialties. This appointment comes at an important time as Adia Med of Winter Park prepares to launch its first Institutional Review Board (IRB)-approved clinical study focused on autism, marking a significant advancement in the Company's clinical and scientific efforts.
お知らせ • Oct 22Adia Nutrition, Inc. Appoints Evan Thomas as Independent Medical Director for Its Medical Division, Adia MedAdia Nutrition, Inc. announced the appointment of Evan Thomas, MD, PhD, as an Independent Medical Director for its medical division, Adia Med. A renowned radiation oncologist and visionary, Dr. Thomas will oversee clinic practices, including the cutting-edge Autologous Hematopoietic Stem Cell Transplantation (AHSCT) program, finalizing protocols to prepare for patient intake once in-network provider status is secured with major insurers. Based in Winter Park, FL, Dr. Thomas serves as Chief Medical Officer of the Renaissance Institute of Precision Oncology &Radiosurgery. He is celebrated for his expertise in central nervous system (CNS) and functional radiosurgery, utilizing stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) to treat complex conditions. Dr. Thomas has pioneered Joint Glow, a therapy utilizing advanced radiotherapy for joint disorders, an innovative approach rare among U.S. physicians. His global influence includes clinical trial leadership, peer-reviewed publications, and lectures in over 15 countries. As Medical Director, Dr. Thomas will guide Adia Med's clinical operations, finalize AHSCT protocols, and oversee Adia Med's other specialized therapies ensuring exceptional patient care.
お知らせ • Sep 11Adia Nutrition, Inc. Appoints Richard Edwards as Its Second Medical DirectorAdia Nutrition, Inc. announced the appointment of Dr. Richard Edwards, DO, as its second Medical Director. Dr. Edwards joins Dr. Monica Sher, MD, to form a diverse and highly experienced board of medical directors. This strategic expansion underscores Adia Nutritions commitment to providing exceptional care and advancing innovative treatments in the field of autologous Hematopoietic Stem Cell Transplantation (aHSCT). Dr. Edwards, a distinguished osteopathic physician, complements Dr. Shers medical expertise with his unique perspective and approach. His extensive background in osteopathic medicine and his dedication to patient-centered care align seamlessly with Adia Nutritions mission to deliver comprehensive and individualized treatment plans. Adia Nutrition is set to move forward with its next crucial step: recruiting oncologists to administer aHSCT treatments. The board and the oncologists will collaborate to review and select the safest and most effective aHSCT protocols from around the world (over 10,000 patients treated by aHSCT worldwide). They will be responsible for crafting detailed protocols and procedures tailored specifically for Adia Nutritions clinics. This process will include determining whether treatments will be administered in a hospital setting or an outpatient clinic, ensuring that all options provide the highest standards of care. In addition to protocol development, the board of medical directors will also be actively involved in evaluating potential patients. Through a thorough assessment process, they will determine which individuals are suitable candidates for aHSCT treatments, based on their medical history and treatment needs.
お知らせ • Aug 23Adia Nutrition, Inc. Announces Appointment of Dr. Monica Sher as One of the Directors of Its Medical DivisionAdia Nutrition, Inc. announced appointment of Dr. Monica Sher as one of the Directors of its Medical Division, where she will be instrumental in helping to establish the policies and procedures for the company's Autologous Hematopoietic Stem Cell Transplantation (aHSCT) program for Multiple Sclerosis (MS) patients. Following a comprehensive search and selection process, Dr. Sher was chosen for her extensive experience and expertise in the field of medicine. With a background in Internal Medicine and a passion for health and wellness, she is well-suited to assist in leading ADIA Nutrition's efforts in advancing aHSCT therapies for MS.
お知らせ • Apr 20Adia Nutrition, Inc. has filed a Follow-on Equity Offering in the amount of $1.5 million.Adia Nutrition, Inc. has filed a Follow-on Equity Offering in the amount of $1.5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 75,000,000 Price\Range: $0.005 to $0.02 Discount Per Security: $0
お知らせ • Jan 08Adia Nutrition, Inc. Appoints Dawn Bell as Chief Revenue OfficerAdia Nutrition, Inc. announced the appointment of Dawn Bell as Chief Revenue Officer (CRO) through its subsidiary, ADIA Labs. Ms. Bell brings more than 15 years of proven expertise as a sales strategist in the medical device and pharmaceutical industries, with a strong history of driving growth and building successful partnerships. While Ms. Bell's role includes strengthening revenue for ADIA Nutrition and its laboratory operations, her primary contribution will be ensuring shared success across the entire ecosystem. She will be partnering with doctors and clinics to significantly increase their revenue by providing hands-on guidance and proven strategies to seamlessly integrate the Company's advanced regenerative therapies and diagnostic services into their practices-whether in regenerative medicine, orthopedics, pain management, wellness, or other specialties. This appointment comes at an important time as Adia Med of Winter Park prepares to launch its first Institutional Review Board (IRB)-approved clinical study focused on autism, marking a significant advancement in the Company's clinical and scientific efforts.
お知らせ • Oct 22Adia Nutrition, Inc. Appoints Evan Thomas as Independent Medical Director for Its Medical Division, Adia MedAdia Nutrition, Inc. announced the appointment of Evan Thomas, MD, PhD, as an Independent Medical Director for its medical division, Adia Med. A renowned radiation oncologist and visionary, Dr. Thomas will oversee clinic practices, including the cutting-edge Autologous Hematopoietic Stem Cell Transplantation (AHSCT) program, finalizing protocols to prepare for patient intake once in-network provider status is secured with major insurers. Based in Winter Park, FL, Dr. Thomas serves as Chief Medical Officer of the Renaissance Institute of Precision Oncology &Radiosurgery. He is celebrated for his expertise in central nervous system (CNS) and functional radiosurgery, utilizing stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) to treat complex conditions. Dr. Thomas has pioneered Joint Glow, a therapy utilizing advanced radiotherapy for joint disorders, an innovative approach rare among U.S. physicians. His global influence includes clinical trial leadership, peer-reviewed publications, and lectures in over 15 countries. As Medical Director, Dr. Thomas will guide Adia Med's clinical operations, finalize AHSCT protocols, and oversee Adia Med's other specialized therapies ensuring exceptional patient care.
お知らせ • Sep 11Adia Nutrition, Inc. Appoints Richard Edwards as Its Second Medical DirectorAdia Nutrition, Inc. announced the appointment of Dr. Richard Edwards, DO, as its second Medical Director. Dr. Edwards joins Dr. Monica Sher, MD, to form a diverse and highly experienced board of medical directors. This strategic expansion underscores Adia Nutritions commitment to providing exceptional care and advancing innovative treatments in the field of autologous Hematopoietic Stem Cell Transplantation (aHSCT). Dr. Edwards, a distinguished osteopathic physician, complements Dr. Shers medical expertise with his unique perspective and approach. His extensive background in osteopathic medicine and his dedication to patient-centered care align seamlessly with Adia Nutritions mission to deliver comprehensive and individualized treatment plans. Adia Nutrition is set to move forward with its next crucial step: recruiting oncologists to administer aHSCT treatments. The board and the oncologists will collaborate to review and select the safest and most effective aHSCT protocols from around the world (over 10,000 patients treated by aHSCT worldwide). They will be responsible for crafting detailed protocols and procedures tailored specifically for Adia Nutritions clinics. This process will include determining whether treatments will be administered in a hospital setting or an outpatient clinic, ensuring that all options provide the highest standards of care. In addition to protocol development, the board of medical directors will also be actively involved in evaluating potential patients. Through a thorough assessment process, they will determine which individuals are suitable candidates for aHSCT treatments, based on their medical history and treatment needs.
お知らせ • Aug 23Adia Nutrition, Inc. Announces Appointment of Dr. Monica Sher as One of the Directors of Its Medical DivisionAdia Nutrition, Inc. announced appointment of Dr. Monica Sher as one of the Directors of its Medical Division, where she will be instrumental in helping to establish the policies and procedures for the company's Autologous Hematopoietic Stem Cell Transplantation (aHSCT) program for Multiple Sclerosis (MS) patients. Following a comprehensive search and selection process, Dr. Sher was chosen for her extensive experience and expertise in the field of medicine. With a background in Internal Medicine and a passion for health and wellness, she is well-suited to assist in leading ADIA Nutrition's efforts in advancing aHSCT therapies for MS.
お知らせ • Apr 20Adia Nutrition, Inc. has filed a Follow-on Equity Offering in the amount of $1.5 million.Adia Nutrition, Inc. has filed a Follow-on Equity Offering in the amount of $1.5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 75,000,000 Price\Range: $0.005 to $0.02 Discount Per Security: $0
